From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population

CRISTIANO FAVA 1,2, MARTINA MONTAGNANA 1,3, GIAN CESARE GUIDI 3 & OLLE MELANDER 1,

1 Department of Clinical Sciences, Lund University, University Hospital of Malmö, Sweden, 2 Department of Medicine, University Hospital of Verona, Italy, and 3 Department of Life and Reproduction Sciences, University Hospital of Verona, Italy

Abstract
Cardiovascular disease (CVD) is the leading cause of death and disability worldwide. In the last decades numerous markers have been considered and investigated for the prediction of CV events, but only a few of them resulted in improved global risk assessment beyond traditional risk factors when incorporated into coronary evaluation scores. Recent genetic studies have pointed out a few but consistent loci or genes which are independently associated with CV risk. The idea is fascinating that these genetic markers could lead to improved individual CV risk assessment and tailored pharmacological interventions.

In this brief review we will not make a systematic review of all non-genetic and genetic markers of CV risk but we will try to make a brief overview of the most interesting ones with the aim to underline potential ‘pros’ and ‘cons’ of their implementation in clinical practice.

Key words: Cardiovascular disease, genetics, marker, risk factor, risk score

Abbreviations
ARIC Atherosclerosis Risk in Communities
CAC coronary artery calcium
CAD coronary artery disease
CAPS Carotid Atherosclerosis Progression Study
CCCC Chin-Shan Community Cardiovascular Cohort Study
CHD coronary heart disease
CHS Cardiovascular Health Study
CNVs copy number variants
CRP C-reactive protein
CVD cardiovascular disease
EBCT electron beam computed tomography
EPIC European Prospective Investigation into Cancer and Nutrition
ESC European Society of Cardiology
FRS Framingham risk score
GCKR glucokinase regulatory
GRS genetic risk score
GWAS genome-wide association studies
HDL high-density lipoprotein
HNR Heinz Nixdorf Recall study
HR hazard ratio
IDI individual discrimination improvement
IL-6 interleukin 6
LDL low-density lipoprotein
Lp-PLA2 lipoprotein-associated phospholipase A2
MCP-1 monocyte chemoattractant protein-1
MDC Malmö Diet and Cancer study
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NACB National Academy of Clinical Biochemistry
NHEFS NHANES I Epidemiologic Follow-up Study
NRI net reclassification improvement
NT-proBNP N-terminal pro-brain natriuretic peptide
OR odds ratio
PREVEND Prevention of Renal and Vascular End-stage Disease
PRIME Belfast Prospective Epidemiological Study of Myocardial Infarction
PROSPER Prospective Study of Pravastatin in the Elderly at Risk
RR risk ratio/relative risk
SCORE Systemic Coronary Risk Evaluation
SNP single nucleotide polymorphism
sPLA2 secretory phospholipase A2
T1DM type 1 diabetes mellitus
T2DM type 2 diabetes mellitus
TRF traditional risk factor
ULSAM Uppsala Longitudinal Study of Adult Men
USPSTF US Preventive Services Task Force
WTCCC Wellcome Trust Case Control Consortium
Introduction
Cardiovascular disease (CVD) is the leading cause of death and disability in developed and developing countries, and in a few years it is predicted to be also in underdeveloped ones (1).
In the last decades numerous markers have been considered and investigated for the prediction of CV events, but only a few of them resulted in improved global risk assessment beyond traditional risk factors (TRFs) such as those incorporated into the Framingham risk algorithms or the Systemic Coronary Risk Evaluation (SCORE) from the European Society of Cardiology (ESC), both in primary and secondary prevention.
The matter in hand is how much the use of these biomarkers, either separately or in combination, can add on top of TRFs in the prediction of CV diseases and, whenever incorporated into the Framingham risk score, which kind of information they give to clinicians to change their behavior in treating individual patients.
In previous studies, new markers were tested in Cox regression models, using TRF as covariates, to assess if they can give independent information about increased cardiovascular risk; consequently it seemed relevant to estimate how much these markers could improve risk discrimination beyond TRFs, i.e. their added value. Thus, in more recent reports, receiver-operating characteristic (ROC) curves, graphical plot of the sensitivity, or true positive rate versus false positive rate were used to evaluate the goodness of fit for newer markers in the evaluation of population risk assessment. The C statistic, by comparison of the area under the curve (AUC) of the risk assessment model with TRF against the model with TRF—the new marker(s) is then used to estimate how much the new marker improves the prediction of the outcome compared to conventional risk evaluation scores alone.
Furthermore, these new markers can improve individual and selective risk assessment by reclassifying subjects, into a more appropriate risk category; especially important is to move high-risk subjects inappropriately classified as low risk by conventional risk factors, from low to a high-risk category when the new biomarker is added. Thus, two new ways of assessing improvement in model performance offered by a new marker were developed (2). The net reclassification improvement (NRI) focuses on reclassification tables constructed separately for participants with and without events and quantifies the correct movement in categories — upwards for events and downwards for non-events. The individual discrimination improvement (IDI) does not require categories; it focuses on differences between integrated sensitivity without sacrificing integrated specificity for models with and without the new marker.
In recent years, through development of newer technologies, genetic studies, now able to investigate the entire genome at once, have pointed out a few but consistent loci or genes that are independently associated with CV risk. Thus, new and commonly
unexpected genes have been related to CV disease and its risk factors: these novel findings have given insight into different mechanisms of action. Thus, although most of researchers in the field would confirm that the primary role of genetics of complex diseases is to add to pathophysiology knowledge and the discovery of pharmacological targets, the idea is fascinating that these genetic markers could lead to improved individual CV risk assessment and tailored pharmacological interventions.

More recently, the Mendelian randomization approach has been used more extensively to investigate possible causal relationships of an intermediate trait (such as C-reactive protein (CRP) levels) with disease. It is a method for obtaining unbiased estimates of the effects of a putative casual variable without conducting a traditional randomized trial. The association between a disease and a polymorphism that mimics the biological link between a proposed exposure and disease is not generally susceptible to the reverse causation or confounding that may distort interpretations of conventional observational studies (3).

In this brief review we will not make a systematic review of all non-genetic and genetic markers of CV risk, but we will try to make a brief overview of the most interesting ones with the aim to underline potential ‘pros’ and ‘cons’ of their implementation in clinical practice. Of interest is also the combination of such markers in panels with the aim to increase cardiovascular disease risk discrimination.

We focused our search especially on population or urban-based cohorts containing prospective evaluations on hard end-points (such as coronary heart disease (CHD) and/or stroke and/or cardiovascular mortality) but included also comments on especially remarkable studies, even if the population was not drawn from the general population. Since we would like to understand if these new biomarkers could add to TRFs, we included only studies in which information about hazard ratio (HR)/relative risk (RR)/odds ratio (OR) after adjustment for TRFs or about discrimination/reclassification of the subjects was available.

**Inflammation markers: CRP, interleukin 6, fibrinogen**

Inflammation plays a pivotal role in atherosclerosis processes, and it is noteworthy that several systemic markers of inflammation, such as CRP, interleukin 6 (IL-6), and fibrinogen, were associated and might predict the risk of cardiovascular events, such as myocardial infarction, ischemic stroke, and sudden cardiac death, in apparently healthy populations (4). For reasons linked to the ease of analysis and accuracy of systemic inflammation prediction even at very low concentration, CRP is to date the most studied one. It is an acute-phase protein produced by hepatocytes in response to factors, such as IL-6, and released by macrophages and fat cells (5). CRP is implicated by several mechanisms in atherogenesis: it stimulates release of endothelial monocyte chemoattractant protein-1 (MCP-1) (6), up-regulates
tissue factor and pro-inflammatory cytokines, induces endothelial adhesion molecules, proteases, and inhibits nitric oxide release (7).

As already stated, several studies have also evaluated the possibility that CRP plays a causal role in atherosclerosis progression, through the Mendelian randomization approach, but most of the interest has been focused on its predictive value as a biomarker (8).

Several investigations have reported that CRP might predict adverse atherosclerotic cardiovascular events, including myocardial infarction, ischemic stroke, and cardiac death independently with respect to TRFs either if used alone or if inserted in a risk algorithm (Supplementary Table I) (9 – 30), whereas other studies did not detect the same independent association (10,31 – 38). Some authors (18,39) have suggested that CRP may even better predict future cardiovascular events than low-density lipoprotein (LDL) cholesterol.

Thus, there is no universal consensus about the value of CRP measurement in the cardiovascular risk assessment. In the Framingham Offspring Study (10), performed on 1,949 men and 2,497 women without CVD, it has been demonstrated that elevated CRP levels provide no further prognostic information beyond TRF assessment to predict future major CVD and major CHD.

A large meta-analysis, including most of the population-based studies presented also in Supplementary Table I, concluded that risk ratios (RR) per 1-SD higher log CRP concentration (3-fold higher) were 1.37 (95% CI 1.27 – 1.48) for CHD, 1.27 (95% CI 1.15 – 1.40) for ischemic stroke, and 1.55 (95% CI 1.37 – 1.76) for vascular mortality, when adjusted for TRFs (40).

Another important limitation is that, even if independently associated with CVD, CRP was found not to improve discrimination as measured by C statistics in most of the studies (10,12,15,19,21,23,24,26,31,32,36,38,41 – 43) and to improve it only marginally in the remaining (the highest improvement in magnitude was 0.015 in the MONICA/KORA Cohort Study sample) (11,14,44) and if included in a multiple biomarker panel (16).

However, some of the same studies found that when CRP is taken into account, either by itself or along with other biomarkers, the reclassification of subjects measured as NRI is significantly increased (9,18,22,26,41,45), suggesting that CRP can be useful in changing the Framingham risk category of selected individuals.

The US Preventive Services Task Force (USPSTF) conducted a systematic review of published prospective cohort, case – cohort, and nested case – control studies relevant to the independent predictive ability of CRP. The authors concluded that only moderate evidence suggests that adding CRP to risk prediction models among initially intermediate-risk persons improves risk stratification (46). In contrast, the National Academy of Clinical Biochemistry (NACB) formed by a multidisciplinary expert panel
to develop laboratory medicine practice guidelines for a subset of emerging risk factors concluded that CRP met all of the stated criteria required for acceptance as a biomarker for risk assessment in primary prevention (47). Guidelines for the evaluation and treatment of major CV risk factors endorsed by international scientific societies consider CRP as a useful marker of inflammation but generally do not advise its routine use; on the other hand guidelines admit that CRP may be useful in guiding therapeutic decision-making for people at intermediate risk (48 – 50).

In the JUPITER trial, subjects with LDL cholesterol of less than 130 mg/dL but with CRP values of more than 2 mg/L were randomized to 20 mg rosuvastatin or placebo. The trial was prematurely stopped because despite the low basal LDL cholesterol the rosuvastatin group showed decreased risk of CV events after a mean follow-up of less than 2 years (51). This is the first demonstration that CRP could help in guiding pharmacologic therapy even if it is impossible to know if the beneficial effect of statin was due to the antilipemic or the ancillary anti-inflammatory properties of this drug.

Regarding other inflammation biomarkers, a meta-analysis of 31 studies (52) showed that fibrinogen has a strong and independent association with CHD, stroke, and vascular deaths, but in several studies, including the Scottish Heart Health Extended Cohort Study (53) and the Framingham Offspring Study (31), despite an independent association with risk of CHD, it failed to add significantly to the discrimination of the Framingham risk score.

The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) (54) reported a significant strong association between elevations in baseline IL-6 levels and fatal CVD, with a hazard ratio for 1 log unit increase in IL-6 of 1.75 (95% CI 1.44 – 2.12). Moreover, the C statistic for fatal CVD using TRFs was slightly but significantly improved by inclusion of IL-6. Also in the Quebec Cardiovascular Study an inflammation score based on plasma IL-6 and fibrinogen levels improved the CHD risk predictive value of a multivariate model of TRF, but the increase was really modest: AUC from 0.705 to 0.713 (32). Similarly, in the Edinburgh Artery study, which followed prospectively 1,592 people aged 55 – 74 years, IL-6, after adjustments for TRFs, was independently associated with cardiovascular events (HR 1.75; 95% CI 1.17 – 2.62), but the AUC augmented only from 0.699 to 0.705, still statistically significant (11). In another cohort, the Cardiovascular Health Study, IL-6 not only improved the AUC (from 0.631 to 0.650), a better increase with respect to CRP and TNF-alpha, but also correctly reclassified 6.6% of the entire cohort and 15.8% of intermediate-risk subjects over TRFs (34).

### Lipid-related markers: lipoprotein associated phospholipase A2 and secretory phospholipase A2

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory enzyme of 45.4 kDa produced by monocytes/macrophages, T lymphocytes,
and mast cells that specifically hydrolyzes oxidized phospholipids on oxidized LDL particles, as oxidized free fatty acids and lysophosphatidylcholine (55). These products stimulate expression of endothelial adhesion molecules and cytokines, leading to recruitment of monocytes to the intima, where they are activated to become macrophages and, ultimately, apoptotic foam cells. These latter produce more Lp-PLA2, which appears to re-enter the blood-stream (56 – 58). It presents high specificity for vascular inflammation, and it is characterized by low biologic variability (59).

Several studies have shown a statistically significant positive association between Lp-PLA2 mass and/or activity and primary cardiovascular events (27,44,48,60 – 67), and other studies have shown a positive association with stroke (63,65,67).

Interestingly, in the MONICA cohort study (44), a 1-SD increase in Lp-PLA2 was associated with a 23% increase in coronary risk, after multivariable adjustment for TRF, and the combination of both elevated Lp-PLA2 and CRP was associated with an even higher CV risk (HR 1.93; 95% CI 1.09 – 3.40). In the meta-analysis by Thompson et al. (68), in which 32 prospective epidemiologic studies for a total of 79,036 participants were included and 17,722 incident outcomes were recorded, 1-SD higher value of Lp-PLA2 activity was associated with CHD (RRs, adjusted for TRFs 1.10; 95% CI 1.05 – 1.16), with ischemic stroke (1.08; 95% CI 0.97 – 1.20), and with vascular mortality (1.16; 95% CI 1.09 – 1.24). No information about discrimination and reclassification were reported in the meta-analysis.

In the Atherosclerosis Risk in Communities (ARIC) cohort, using a case – cohort design, different inflammatory markers were measured with the aim to evaluate if they could add to the discrimination provided by TRFs: Lp-PLA2 was shown to be independently associated to CHD and to be the only marker able to augment the AUC determined by TRFs even if the magnitude of the increase was quite modest (from 0.774 to 0.780) (19).

In a sample from the Rancho Bernardo Study (n _1,077 older adults), although the addition of CRP to a model including age, gender, hypertension, diabetes, smoking, and exercise did not change the AUC for CHD (0.595 versus 0.595), further addition of Lp-PLA2 significantly increased the AUC to 0.617 (42).

Finally, using a nested case – control study among participants of the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study, a prospective population study in UK, Rana and colleagues selected 921 cases, who experienced CHD, and 1,629 controls. The AUC was not significantly different between the groups if Lp-PLA2 was added to the model group (0.59 versus 0.59). Also the NRI was modest, being 1.1% in the entire cohort and 8.8% in the subjects at intermediate risk (45).

To date, Lp-PLA2 testing is not recommended in low-risk populations as a screening tool, but it
could be recommended in patients at moderate risk, determined as having simply two risk factors and high 10-year risk (patients with coronary artery disease (CAD) or CAD risk equivalents) (69). Secretory phospholipase A2 (sPLA2) is a Ca$_2^+$-dependent enzyme belonging to the group of acute-phase reactants (70) which produces free fatty acid and lysophospholipid from membrane phospholipids (71).

The role of sPLA2 in prediction of CV events in healthy subjects has been investigated in a small number of prospective studies. In these studies the prognostic value of sPLA2 was significantly independent of TRF and various biochemical markers, with OR between 1.34 and 3.46 (45,72 – 76), but further confirmation in larger samples is expected. To our knowledge, the only study which evaluated the discrimination and reclassification for sPLA2 was the already cited EPIC-Norfolk study: AUC for CHD from 0.59 to 0.61 ($P < 0.058$), and the NRI was 6.4% in the entire risk spectrum and 16.3% in the intermediate-risk group (45).

Cardiospecific markers: N-terminal pro-brain natriuretic peptide (NT-proBNP)

Several prospective studies have indicated a significant association between circulating concentration of natriuretic peptides and CVD risk in the general population (9,15,16,26,31,35,60,77 – 80) (Supplementary Table II). Accordingly, in a meta-analysis of different prospective studies, by analyzing individuals in the top third with those in the bottom third of base-line values of natriuretic peptides, the combined relative risk ratio (RR), adjusted for several conventional risk factors, was 2.82 (95% CI 2.40 – 3.33) for CVD (81). Despite these evidences, NT-proBNP failed to enhance prediction beyond established risk factors as measured by C statistics in the Malmö Diet and Cancer study (MDC) (16), in the Uppsala Longitudinal Study of Adult Men (ULSAM) (9), in a prospective Danish study (15), and in the PRIME cohorts (26). However, in contrast to the MDC, the PRIME and ULSAM studies found a higher NRI. In the Rotterdam study, AUC for total cardiovascular, coronary, and stroke events significantly improved after adding the NT-proBNP to a model based on TRFs, as well as reclassification for total cardiovascular events (80).

Highly sensitive troponins

In some studies also troponin (Tn) I and/or T were used as prognostic markers in the population (60,82). In the Rancho Bernardo Study, participants with detectable TnT had an increased risk of cardiovascular death (HR 2.06; 95% CI 1.03 – 4.12) with a reclassification of 4% of participants into a high-risk group, based on TnT detectability. Also, TnT significantly improved the AUC for the prediction of CVD mortality compared with the Framingham risk score (FRS) alone (AUC 0.668 versus 0.597) (60). More recently, new cardiac Tn assays, defined as 'highly sensitive' and characterized by a higher analytic sensitivity, were introduced also in the prospective
evaluation of general population cohorts: in the Cardiovascular Health Study (CHS), during a median follow-up of 11.8 years, 1,103 cardiovascular deaths occurred, with a greater risk of this end-point associated with higher sensitive cTnT concentrations. However, addition of base-line cTnT measurements to TRFs was associated with only modest improvement in discrimination, with a change in C statistic of only 0.013 (83). In the Dallas Heart Study, after adjustment for TRF and other biomarkers, cTnT category remained independently associated with all-cause mortality (HR 2.8; 95% CI 1.4 – 5.2, in the highest category) but not with CV mortality. Adding cTnT categories to the fully adjusted mortality model modestly but significantly improved the model fit and the IDI (0.010) (84). Finally, in the FINRISK97 and in the PRIME studies sensitive TnI was used to test the association with incident cardiovascular events at 10 years (26). It slightly improved discrimination only in FINRISK97 males (AUC from 0.817 to 0.820; \( P < 0.001 \)) and reclassification in FINRISK97 males and females (IDI 0.008 and 0.004, respectively; \( P < 0.05 \) for both), but not in PRIME.

Renal function marker: cystatin C
Cystatin C, a protease inhibitor of 13 kDa synthesized in all nucleated cells, is an expression of renal function, and it is directly involved in the atherosclerotic process (85). Prospective studies have shown that patients with increased cystatin C are at a higher risk of developing CVD (9,16,26,86 – 89), but, where evaluated, discrimination and reclassification did not significantly improve (9,16,26).

Multiple biomarker panels
The combination of multiple biomarkers into an integrated score or algorithm, rather than the use of individual markers, may be a way to enhance CV risk stratification (9,16,26,31). In the study by Zethelius, with the combination of TnI, NT-proBNP, cystatin C, and CRP, the C statistic relative to deaths from cardiovascular causes increased from 0.66 for the TRF model alone to 0.77 when the panel of biomarkers was added and from 0.69 to 0.75 in the subgroup that was free of CVD at base-line (9). A biomarker score was developed also from the FINRISK97 cohort, where 30 different biomarkers were individually tested. The score included sensitive TnI, CRP, and NT-proBNP. Adding this score to a conventional risk factor model in the PRIME male cohort validated it by improved C statistics (AUC from 0.67 to 0.70) and led to significant reclassification of individuals into risk categories (NRI 0.11; \( P < 0.001 \), and significantly improved also IDI) (26). However, in the Malmö Diet and Cancer (16) and Framingham Heart Study (31) the increment in the C statistic after adding combinations of newer biomarkers over the model with TRF was very small and non-significant.

Imaging markers
Also ‘markers’ of subclinical atherosclerotic damage could add to the predictive value of TRFs: in
particular intima–media thickness (IMT) is an easily performed and reproducible measure of atherosclerotic progression, especially at carotid artery level. Indeed, coronary calcium as detected by electron beam computed tomography, although it exposes patients to radiation and is not indicated as a screening tool in young populations, has been proposed as a reliable measure of atherosclerosis progression at coronary artery sites. Both exams have been proposed as powerful predictors of successive hard coronary and cerebrovascular events beyond TRF.

**Intima–media thickness**

In numerous population-based prospective studies carotid IMT, other than carotid plaque, was significantly (or border-line significantly) associated to incident coronary and cerebrovascular events, even after TRF adjustment (Supplementary Table III) (24,25, 90 – 107), but as for circulating biomarkers there is seldom evidence of an increase in discrimination and reclassification (24,90,94,102,103,108). In a community-based cohort study in a Chinese population a significant association was found between carotid IMT and incidence of CHD and stroke in Chinese adults, but neither the AUC for CHD nor that for stroke significantly improved after IMT addition to the TRF model (103). Also the NRI was not significantly increased, although a modest but significant increase in the IDI was evident (103). In the Multi-Ethnic Study of Atherosclerosis (MESA), evaluating incident CVD events (CHD, stroke, and fatal CVD) over a maximum of 5.3 years of follow-up, not only was coronary artery calcium (CAC) associated more strongly than carotid IMT with the risk of incident CVD, but a ROC analysis also suggested that CAC score was a better predictor of incident CVD than was IMT, with AUC of 0.81 versus 0.78, respectively, after adjustment for TRFs (102). More recently, in the Atherosclerosis Risk in Communities (ARIC), after more than 15 years of follow-up and 1,812 CHD events, a significant improvement was found in discrimination (AUC from 0.742 to 0.755) and a reclassification to high risk up to 20.5%. The carotid IMT plus TRFs plus plaque model had the best NRI of 9.9% in the overall population (108).

**Coronary calcium**

Several studies have evaluated the coronary calcium score for the prospective assessment of major CV events in patients at augmented CV risk (109 – 112), but a few have evaluated it in population-based cohorts (Supplementary Table IV) (101,102, 113 – 120). As stated before, in the MESA cohort the CAC score was preferable to IMT in discrimination and reclassification of subjects for CHD (102). In the same prospective cohort, in an analysis focused on coronary events, the ROC-AUC was significantly increased moving from 0.77 to 0.82 for total coronary events and from 0.79 to 0.83 for major coronary events (119). Also in the South Bay Heart Watch, in the St Francis Heart Study, in the Rotterdam study, and in the Heinz Nixdorf Recall (HNR)
study, the AUC for CVD significantly improved but with a maximum of 0.07, suggesting that the clinical significance on top of TRFs could remain poor. On the other hand, in all these studies, a significant increase, at least in the NRI, was observed (113,116 – 119).

Trying to summarize all these studies, it seems clear that even if new markers, which can in dependently predict future CV diseases, have been successfully and unequivocally found, their contribution to risk prediction is at best small, when TRFs and/or risk score based on TRFs are taken into account, especially if the investigated population is at average low basal risk.

### Genetic markers

CVD is a complex genetic trait, and the genomewide association studies (GWAS), by scanning millions of loci without any a-priori biological hypotheses, have led to the identification of approximately 160 loci associated with CVD and its risk factors (121). The risk in association with any single genotype is modest (between 1.12 and 1.73) (122), and so far new and old genetic variants have demonstrated to confer only small to moderate advantages in terms of discrimination and individual reclassification of risk when added to TRFs. However, in combination, selected genotypes may be associated with a clinically significant risk, and this approach might aid in the identification of high-risk individuals in whom correction of "modifiable risk factors" through life-style interventions or medication would be most beneficial (122).

Many case–control GWAS have reported an incontrovertible link between chromosome 9p21 and the risk of coronary artery disease (50,123 – 125). The association was replicated in large samples such as the MORGAM prospective cohorts, including 33,282 subjects from Finland, Sweden, France, and Northern Ireland (SNP rs1333049), where a significant association was found also for stroke (126).

A recent meta-analysis confirmed the association of SNPs contained in the 9p21 locus and myocardial infarction (MI), but overall the effect size of the added risk was very modest (127).

Other GWAS have indicated different loci (50,128,129): e.g. the Wellcome Trust Case Control Consortium (WTCCC) identified 2q36.3 and 6q25.1, a finding replicated in the German MI Family Study (123) but not in other populations (130). Anyhow, the capacity of newer genetic loci of predicting future CV risk is estimated to be modest. Strong and reproducible results were reached in GWAS and other association studies related to lipid metabolism: GWAS have so far identified 43 loci involved with lipoprotein metabolism (131,132).

For example, SNPs consistently associated to LDL levels were located in previously identified loci (ABCA1, APOA5-APOA4-APOC3-APOA1 and APOE-APOC clusters, APOB, CETP, GCKR, LDLR, LPL, LIPC, LIPG, and PCSK9) and new ones (CELSR2-PSRC1-SORT1) (133,134). Eleven of the SNPs associated with LDL level were also
associated with MI (131). Interestingly, allele A at rs599839, associated with an increase of 5.48 mg/dL in LDL cholesterol concentrations (132), had been found to confer an increased risk of CAD also in a previous study (123).

Genetic variants in MLXIPL, TRIB1, ANGPTL3 have been consistently associated with triglyceride concentration, but the added risk on cardiovascular disease still remains hypothetical (133 – 135). Another functional SNP, rs780094 within the coding region of the glucokinase regulatory (GCKR) gene, was strongly associated with triglyceride levels (133). Regarding high-density lipoprotein (HDL) cholesterol, the strongest evidences of association point to SNPs located in the CETP locus, at chromosome 16q13 (133,136) and GALNT2 (133,134). Recently it has been reported that multiple loci on chromosome 6q26-q27 contribute to Lp(a) levels (137,138) and that two single nucleotide variants at the LPA locus were strongly associated with a small Lp(a) lipoprotein size, increased levels of Lp(a) lipoprotein conferring an increased risk of coronary disease.

However, after adjustment for the Lp(a) lipoprotein level, the association between the SNPs and the risk of coronary disease disappeared (139).

Other genetic determinants of the increase of CV risk involve gene polymorphisms that predispose to diabetes mellitus. Accordingly, GWAS have identified several type 1 (140 – 142) and type 2 (143 – 145) diabetes mellitus susceptibility loci, and several prediction models to assess disease risk using SNPs consistently associated with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) are being tested (140,146 – 148).

Even if initially inconsistent results have been obtained from GWAS for blood pressure and hypertension (50), recent studies have found several loci and reliable candidate genes (149 – 153), although further replications are needed. Given the linear relationship between blood pressure and CV risk, these gene variants are likely to be linked to CVD, but this still remains to be proven.

Some studies have evaluated also the putative risk conferred by SNPs in the genes codifying for the new CV biomarkers. The Mendelian randomization approach has been used to test if the relationship between elevated CRP levels in plasma and CHD is causal or not (3,8,154 – 156). It was shown that genetically mediated elevation of CRP was not associated with CHD, strongly arguing for a causal role of CRP in the pathogenesis of CHD. This type of clinical application of genetics is extremely useful, as proof of causality between a novel risk factor and CHD is the strongest indication that development of new drugs that alter the risk factor level in question will actually reduce incidence of the disease in question.

Also the association between polymorphisms in the lipoprotein-associated phospholipase A2 gene (PLA2G7) with both Lp-PLA concentration and cardiovascular diseases was investigated, with controversial results (157 – 159).
**Genetic risk scores**

Morrison et al. included into a single genetic risk score (GRS) several SNPs selected from both candidate genes and genes identified through large-scale genomic association studies of CHD. In the Atherosclerosis Risk in Communities (ARIC) cohort the GRS was significantly associated with incident CHD in blacks (hazard rate ratio (HRR) 1.20; 95% CI 1.11–1.29) and whites (HRR 1.10; 95% CI 1.06–1.14). When ROC curves based on TRFs were recalculated after the GRS was added, the increase in prediction was really modest, even if statistically significant (160). More recently, Anderson and colleagues, within the Intermountain Healthcare’s Coronary Genetics (CorGen) project, used a GRS to evaluate the association with premature CAD (1,947 cases) using CAD-free controls (n = 1,036) in a cross-sectional study. Five variants contributed jointly to CAD prediction in a multigenic GRS model: OR 1.24 (95% CI 1.16–1.33) per risk allele, adjusted OR 2.03 (1.53–2.70), fourth versus first quartile. The five SNPs’ GRS score had a minor impact on AUC (P = 0.05) but resulted in substantial NRI (0.16 overall, 0.28 in intermediate-risk patients; both P = 0.0001), a result confirmed in a validation set consisting of 318 cases with premature CAD (161). A genotype score, on the basis of the number of unfavorable alleles, of nine validated SNPs relative to LDL and HDL cholesterol has been tested for CVD prediction also in the MDC Study. This appears as an independent risk factor for incident CV disease, even if it does not improve risk discrimination beyond standard clinical factors (162). Thus, similarly to circulating/imaging biomarkers, the actual contribution of genetic markers to risk prediction is small. Nevertheless new horizons are opening for the genetics of complex diseases.

**New genetic approaches for CV risk assessment**

Through GWAS and candidate gene studies, several common SNPs associated with CV diseases have been found. Although these studies have provided new biological insights, only a limited amount of the heritable component of any complex trait has been identified. Technological advances, such as the ability to detect rare and structural variants, detection of regulatory RNA, expression studies, epigenetics, and whole-genome sequencing, will be essential for future progress. Deletions and duplications of chromosomal segments (copy number variants (CNVs)) are a major source of variation between individual humans and are an underlying factor in human evolution and in many diseases (163). CNVs are not captured in usual GWAS, and specific methods to quantify CNVs are used. In a large study promoted by the Myocardial Infarction Genetics Consortium, CNVs were assessed for association with early-onset myocardial infarction in 2,967 cases and 3,075 controls: unfortunately none of the CNVs were detected as a greater CNV burden in cases compared to controls (130). Anyhow, other potentially meaningful variants, such as ins/del, are not tested by these
approaches. The gene – environment interactions relevant for complex diseases are regulated by epigenetic mechanisms such as histone acetylation and DNA methylation. Epigenetic processes modulate gene expression patterns without modifying the actual DNA sequence and have profound effects on the cellular repertoire of expressed genes. There are now many microarray-based techniques available to measure cytosine methylation across the genome allowing ‘ epigenome-wide association studies (eGWAS) ’ as well as gold-standard techniques available for analysis of a smaller, more targeted set of loci (164,165). Furthermore, genome-wide allele-specific approaches, that use high-throughput sequencing technology, have started to allow direct evaluation of how cis-regulatory polymorphisms control gene expression and affect chromatin states (166). Some evidences using this approach are coming especially for cancer-related research (167) but are almost completely lacking for CV disease research. Recently, pathway-based approaches have been developed, which use prior biological knowledge on gene function to facilitate more powerful analysis of GWAS data sets. These approaches typically examine whether a group of related genes in the same functional pathway are jointly associated with a trait of interest (149,168). Moreover, the simultaneous genome-wide assay of gene expression and genetic variation allows the mapping of the genetic factors that underpin individual differences in quantitative levels of expression (eQTLs). The availability of systematically generated eQTL information could provide immediate insight into a biological basis for disease associations identified through GWAS and can help to identify networks of genes involved in disease pathogenesis (169). Finally, it is easy to prognosticate that whole-genome sequencing will facilitate substantial progress in the field, especially if a substantial part of the missing genetic control is due to gene variants that are too rare to be picked up by GWAS and have relatively large effects on risk (170). The full genome sequence of individual patients has been already used for risk prediction of CAD and T2DM (171).

**Final considerations**

Thus, even if it might seem that — at the current stage — not only circulating/imaging biomarkers but also the newer genetic markers cannot add very much to clinically assessed risk in term of discrimination and reclassification of subjects at risk for CV disease, it can be expected that in the near future new horizons will be opening. A possible advantage of genetic (based on DNA) markers over conventional and newer ones is their ‘ stability ’ over time. For example, triglyceride levels or even blood pressure measurements are modifiable by disturbing factors such as recent food ingestion or the white coat effect, etc. Thus, the possibility that genetic markers could be even more accurate than biochemical results or clinical assessment of conventional risk factors in deciding the beginning of a specific therapy is an attractive hypothesis. It is possible to conceive that a panel of either SNPs or tandem
repeats or epigenetics modifications in genes/loci implicated in cholesterol metabolisms could guide therapy better than single or even repeated measurements of LDL cholesterol. The same can be hypothesized for hypertension management or ischemic heart disease prevention. As for the JUPITER study, where CRP was used as a discriminatory variable to be included in the intervention harm of the trial, it remains to be tested if some genetic markers could drive preventive therapy in the future.

Future development in pharmacogenetics/genomics could also help in guiding drugs choice in fields where different medications are available and the choice is often guided by a ‘trial and error’ procedure that sometimes could put at disadvantage the final compliance to therapy by patients.

Another possible advantage in the use of genetic markers is the fact that they are detectable and maybe potentially useful at a younger age when, for example, cholesterol or blood pressure are perfectly in the normal range. Carriers of high-risk polymorphisms could benefit from changes in their life-style before developing the risk factor. In fact, in contrast to other fields, such as in the prevention of some cancers or degenerative diseases where very few possibilities exist and the burden of the genetic diagnosis is probably more harmful than beneficial, in CVD a healthy life-style, such as a Mediterranean diet or exercise, has been demonstrated to be effective (172,173), and other preventive strategies also with pharmacological agents could be experimented with.

Thus, even if the major and more recognizable benefit of genetic research is the discovery of new pathophysiological pathways and possible new pharmacological targets, with the increase of knowledge and technical tools several other potential utilities in risk prediction and newer clinical applications could be addressed.

To conclude, it has to be recognized that, to date, both for genetic and circulating biomarkers, what is added in terms of discrimination and reclassification of future CV disease is relatively little. Imaging markers, such as IMT and coronary calcium score, may be used for cardiovascular risk assessment in asymptomatic subjects at intermediate risk, as recently stated also in the AHA/ACC report (174), but their added value is still debatable.

The research in this field is open, currently developing, and potentially very fruitful. Some possible advantages of genetic markers over conventional ones deserve attention and are probably promising of a future unexpectedly not so far distant. As reported by Dr Alan E. Guttmacher, ‘That era will be soon upon us and, unless we prepare now, we will not have the scientific, logistical and ethical framework that is required for the appropriate and effective use of genomic information.’ (175).

Declaration of interest: The authors have no conflict of interest to declare.
References
35. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.


69. Davidson MH, Corson MA, Alberts MJ, Anderson JL,


Supplementary material available online
Supplementary Table I.
Supplementary Table II.
Supplementary Table III.
Supplementary Table IV.
<table>
<thead>
<tr>
<th>Population</th>
<th>Cardiovascular outcome (N)</th>
<th>Follow-up</th>
<th>Results after adjustment for TRF</th>
<th>Discrimination and reclassification (on top of TRF)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>FINRISK97 (N=3,870 men and N=4,045 women, aged 25 to 74 years, in Helsinki)</td>
<td>CVE in Finrisk (376 in men and 162 in women)</td>
<td>over 10 years</td>
<td>CVE in Finrisk97 male: *1.23 (1.13-1.35); **1.78 (1.27-2.48); CVE in Finrisk female: *1.24 (1.07-1.44); **1.29 (0.76-2.18); CVE in PRIME 1.27 (1.13-1.41); **1.38 (0.98-1.95)</td>
<td>FINRISK97 male: AUC from 0.817 to 0.820 n.s.; female from 0.876 to 0.877 n.s. PRIME from 0.666 to 0.680</td>
<td>Blankenberg 2010 (26)</td>
</tr>
<tr>
<td>PRIME (N=2,551 men aged 50 to 59 years, in Belfast)</td>
<td>CVE in PRIME (260)</td>
<td></td>
<td></td>
<td>In PRIME NRI (p&lt;0.05)</td>
<td></td>
</tr>
<tr>
<td>Health, Aging, and Body Composition study (N=2,225 participants, aged 70 to 79 years, surrounding Pittsburgh, Pa, and Memphis)</td>
<td>CHD events (351)</td>
<td>median of 8.2 years</td>
<td>CHD: **1.31 (0.95-1.82)</td>
<td>CHD: AUC from 0.631 to 0.638 (non specified) Better model fit by Likelihood Ratio Test but not better calibration by Hosmer-Lemeshow Test</td>
<td>Rodondi 2010 (34)</td>
</tr>
<tr>
<td>Health, Aging, and Body Composition study (N=1,004 subjects, aged 73.6±5.2 on average, in Bordeaux, Dijon, Montpellier, France)</td>
<td>CHD (174)</td>
<td>till 4 years</td>
<td>CHD: **1.87 (1.09-3.25) *1.21 (0.99-1.47)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iwate-Kenpoku Cohort study (N=7,901 men, aged 64.0 years o average, Japan)</td>
<td>Stroke (130)</td>
<td>average of 2.7 years</td>
<td>Stroke: **1.77 (1.04-3.03)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(EPIC)-Norfolk study (N=25,663 men and women, aged 45-79 years, resident in Norfolk, UK)</td>
<td>CHD (1005)</td>
<td>over a 10-year period</td>
<td>CHD: *men 1.13 (1.01-1.26), women 1.18 (1.02-1.36)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDC (N=5,067 participants, aged 58 years on average, in Malmö, Sweden)</td>
<td>CVE (418)</td>
<td>median of 12.8 years</td>
<td>CVE: *1.19 (1.07-1.32)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOMAS (N=2,240 participants, aged 68.9±10 years on average, in Northern Manhattan, US)</td>
<td>Stroke (196)</td>
<td>median of 7.9 years</td>
<td>Stroke: **1.17 (0.79-1.74)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MI (158)</td>
<td></td>
<td>MI: **1.70 (1.04-2.77)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vascular deaths (246)</td>
<td></td>
<td>Vascular deaths: **1.57 (1.07-2.30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chin-Shan Community Cardiovascular Cohort (N=2,897 participants, aged &gt;35 years, Taipei City, Taiwan)</td>
<td>Stroke (65)</td>
<td>median of 5.3 years</td>
<td>Stroke: **2.63 (1.06-6.53)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>nested case-control study (N=130)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Framingham Offspring Study participants (N=3,006 participants, aged 46 years on average)</td>
<td>CHD (129)</td>
<td>over 12 years</td>
<td>CHD: *1.34 (1.14-1.58),**1.88 (1.18-3.00)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total CVD (286)</td>
<td></td>
<td>CVD: **1.26 (1.12-1.40), **1.58 (1.16-2.15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>nested case-control study (N=130)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Framingham Offspring Study participants</td>
<td>CHD (129)</td>
<td>over 12 years</td>
<td>CHD: *1.34 (1.14-1.58),**1.88 (1.18-3.00)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total CVD (286)</td>
<td></td>
<td>CVD: **1.26 (1.12-1.40), **1.58 (1.16-2.15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>nested case-control study (N=130)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Participants</td>
<td>Age Range</td>
<td>Follow-up</td>
<td>Outcomes</td>
<td>Hazard Ratio</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>--------------</td>
<td>-----------</td>
<td>-----------</td>
<td>----------</td>
<td>------------------</td>
</tr>
<tr>
<td>ULSAM (N=1,135 participants, with mean age 71 years at baseline, Uppsala, Sweden)</td>
<td>CV mortality (136)</td>
<td>Median of 10 years</td>
<td>CV mortality: *1.49 (1.12-1.98); **2.72 (1.56-4.73)</td>
<td>From 0.688 to 0.715 n.s.</td>
<td></td>
</tr>
<tr>
<td>Hisayama study (N=2,589 participants, aged ≥40 years or older, in Hisayama, Japan)</td>
<td>CE (129)</td>
<td>Up to 14 years</td>
<td>CE: **2.98 (1.53-5.82)</td>
<td>Not provided</td>
<td></td>
</tr>
<tr>
<td>Sample from the Rancho Bernardo Study (N=1,077 older adults, in Southern California, US)</td>
<td>CV mortality (158)</td>
<td>Mean of 16 years</td>
<td>CV mortality: 3.00 (1.70-5.28)</td>
<td>CHD: AUC from 0.595 to 0.595 n.s.</td>
<td></td>
</tr>
<tr>
<td>Framingham Offspring Study participants (N=3,782 participants, aged 55±10 years on average)</td>
<td>CVE (347)</td>
<td>Mean 8 years, range 4.6-10.1 years</td>
<td>CVE: **1.31 (0.81-2.10) for men and 1.74 (0.97-3.13) for women</td>
<td>AUC from 0.78 to 0.78 n.s.</td>
<td></td>
</tr>
<tr>
<td>CHS (N=5,020 participants, without baseline CVD, aged ≥65 years, US)</td>
<td>MI (595)</td>
<td>Till 12 years</td>
<td>MI: **1.33 (1.11-1.60) stroke: **1.26 (1.05-1.51)</td>
<td>MI: from 0.680 to 0.683 n.s. Stroke: from 0.686 to 0.687 n.s. CVD mortality: from 0.742 to 0.748 n.s. Composite CVD: from 0.684 to 0.687 n.s.</td>
<td></td>
</tr>
<tr>
<td>Edinburgh Artery Study (N=1,592 men and women, aged 55 to 74 years, in Edinburgh, UK)</td>
<td>CVE (293)</td>
<td>Mean of 17 years</td>
<td>CVE: **1.78 (1.30-2.45)</td>
<td>AUC from 0.692 to 0.700 p&lt;0.05</td>
<td></td>
</tr>
<tr>
<td>N=2,656 individuals, aged 41, 51, 61, and 71 years old, from the population near Glostrup University Hospital, Denmark</td>
<td>CEP (219)</td>
<td>9.4 years</td>
<td>CEP: **1.22 (1.05-1.42) CV death: **1.27 (1.03-1.57)</td>
<td>CEP: AUC from 0.82 to 0.83 n.s. CV death: AUC from 0.87 to 0.88 n.s.</td>
<td></td>
</tr>
<tr>
<td>Part of the Copenhagen Holter study (N=638 participants, aged 55-75 years, Denmark)</td>
<td>Deaths or MI (57)</td>
<td>Till 5 years</td>
<td>Deaths or MI: *1.63 (0.83-3.20)</td>
<td>Not provided</td>
<td></td>
</tr>
<tr>
<td>Sixth examination of the Framingham Offspring Study (N=3,209 participants, aged on average 59±10 years, Framingham, US)</td>
<td>Major CVE (169)</td>
<td>Median of 7.4 years</td>
<td>Major CVE: *n.s.</td>
<td>CRP was excluded from the model for discrimination</td>
<td></td>
</tr>
<tr>
<td>ARIC (N=15,792 adults aged 45 to 74 years and sampled from 4 US communities)</td>
<td>CHD (666)</td>
<td>Median follow-up was 7.3 years</td>
<td>CHD: *1.17 p&lt;0.01</td>
<td>AUC from 0.767 to 0.770 n.s.</td>
<td></td>
</tr>
<tr>
<td>Copenhagen Study (N=764 participants, aged 50 to 89 years from the municipality of Frederiksberg, Denmark)</td>
<td>First major CVE (65)</td>
<td>Median of 5.0 years</td>
<td>First major CVE: **1.02 (95% CI, 0.56-1.85); *1.15 (0.88-1.51)</td>
<td>Not provided</td>
<td></td>
</tr>
</tbody>
</table>
| CHS (N=3,971 men and women ≥65 years of age) | CHD (547) | 10 years | CHD: **1.45 (1.14-1.86) | Better reclassification in intermediate-Framingham-
<table>
<thead>
<tr>
<th>Study/Study Details</th>
<th>Duration</th>
<th>Outcome Measure</th>
<th>Hazard Ratio (95% CI)</th>
<th>Area Under Curve (AUC)</th>
<th>P-Value</th>
<th>Reference Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quebec Cardiovascular Study (N=1,982 men, aged 35-64 years the Quebec City metropolitan area, Canada)</td>
<td>over a period of 13 years</td>
<td>CE: **0.98 (0.65-1.49)</td>
<td>CE: AUC from 0.705 to 0.706 n.s.</td>
<td>St. Pierre 2005 (32)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reykjavik prospective study (cases N=2,459 and controls N=3,969, aged on average 55 years in Reykjavik, Iceland)</td>
<td>average of 17.5 years (cases) and 20.4 years (controls)</td>
<td>CE: **1.45 (1.25-1.68)</td>
<td>CE: from 0.64 to 0.65 n.s.</td>
<td>Danesh 2004 (21)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(N=3,213 men, aged 49 to 66 years from the general populations of Caerphilly and Speedwell, UK)</td>
<td>average of 90 months</td>
<td>CHD: **1.72 (1.14-2.58), *1.19 (p&lt;0.01)</td>
<td>Not provided</td>
<td>Lowe 2004 (29)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Framingham Offspring Study participants (N=3,037 participants, aged 55±10 years on average)</td>
<td>average of 6.9±1.2 years</td>
<td>Not provided</td>
<td>CVD: from 0.72 to 0.74 n.s.</td>
<td>Rutter 2004 (43)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARIC (N=15,792 adults, aged 45 to 74 years and sampled from 4 US communities)</td>
<td>till 11 years</td>
<td>CHD: **1.72 (1.24-2.39)</td>
<td>Not provided</td>
<td>Ballantyne 2004 (27)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(N=3,435 white men 45 to 74 years of age; Augsburg area, Southern Germany)</td>
<td>average of 6.6 years</td>
<td>CE: **2.03 p&lt;0.01</td>
<td>CE: from 0.735 to 0.750; p&lt;0.05</td>
<td>Koenig 2004 (18)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular Health Study (N=5,417 participants aged 65 years or older without preexisting stroke or chronic atrial fibrillation)</td>
<td>Ischemic stroke (469) 10.2 years</td>
<td>Ischemic stroke: **1.60 (1.23-2.08)</td>
<td>Not provided</td>
<td>Cao 2003 (25)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health, Aging, and Body Composition study (N=2,225 participants, aged 70 to 79 years, near Pittsburgh, Pa, and Memphis)</td>
<td>average of 3.6 years</td>
<td>CHD: *1.11 (0.96-1.29), **1.20 (0.83-1.75)</td>
<td>Not provided</td>
<td>Cesari 2003 (37)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotterdam Study, (N=7,983 people ≥55 years in Rotterdam, the Netherlanda)</td>
<td>max of 8 years</td>
<td>MI: **1.2 (0.6-2.2)</td>
<td>MI: AUC from 0.746 to 0.748 n.s.</td>
<td>van der Meer 2003 (38)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nested case-control (N=657)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRIME (N=9,758 men aged 50 to 59 years, in France and Northern Ireland)</td>
<td>5 years</td>
<td>MI and coronary death: **2.16 (1.26-3.72)</td>
<td>MI and coronary death: **2.16 (1.26-3.72)</td>
<td>Luc 2003 (28)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nested case control study (N=926)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Framingham Study original cohort (N=591 men and N=871 women free of stroke/TIA,</td>
<td>12 to 14 years of follow-up</td>
<td>Men: **1.248 (1.012-1.539)</td>
<td>Not provided</td>
<td>Rost 2001 (13)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Women: **1.288 (1.073-1.546)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
aged 69.7 years on average)

N, number; HR, hazard ratio; RR, relative risk; TRF, traditional risk factors; CV, cardiovascular; CVE, cardiovascular events; CE, coronary events; MI, myocardial infarction; CEP, combined CV endpoint (CV death, stroke, or MI); TIA, transient ischemic attack; n.s. non significant; NRI, Net reclassification improvement; IDI, individual discrimination improvement; EPIC, European Prospective Investigation into Cancer and Nutrition; MDC, Malmö Diet and Cancer; ULSAM, Uppsala Longitudinal Study of Adult Men; CHS, Cardiovascular Health Study; NOMAS, Northern Manhattan Study; ARIC, Atherosclerosis Risk in Communities; PRIME, Belfast Prospective Epidemiological Study of Myocardial Infarction.

*HR in Relation to a 1-SD Increment of plasma CRP (in some studies the value of CRP was log transformed).

**HR in the highest CRP category with respect to the reference (lowest) CRP category.
### Supplementary table 2: BNP/NT-pro-BNP and prediction of future cardiovascular events in the community (general population).

<table>
<thead>
<tr>
<th>Population</th>
<th>Cardiovascular outcome</th>
<th>Follow-up</th>
<th>Results after adjustment for TRF</th>
<th>Discrimination and reclassification on top of TRF</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>PREVEND (N=8,383 individuals age on average 49.3±12.7 years)</td>
<td>CV events (557)</td>
<td>median of 7.5 years</td>
<td>CV events: 1.16 (1.05-1.29)</td>
<td>Not provided</td>
<td>Linssen 2010 (78)</td>
</tr>
<tr>
<td>FINRISK97 (N=3,870 men and 4045 women aged 25 to 74 years, in Helsinki)</td>
<td>CVE in Finrisk (376 men and 162 women)</td>
<td>over 10 years</td>
<td>Finrisk97 male: *1.23 (1.13-1.34); **1.14 (0.82-1.59)</td>
<td>FINRISK97 male: AUC from 0.817 to 0.820 n.s.; female from 0.876 to 0.883 n.s.</td>
<td>Blankenberg 2010 (26)</td>
</tr>
<tr>
<td>PRIME (N=2,551 men aged 50 to 59, in Belfast)</td>
<td>CVE in PRIME (260)</td>
<td>average of 4.6 years</td>
<td>CVE events male: **2.32 (1.55-2.70) female 3.08 (1.91-3.74); CHD male **2.01 (1.14-2.59) female 2.95 (1.30-4.55); stroke male: **2.06 (0.91-3.18) female 2.07 (1.00-2.97)</td>
<td>PRIME 1.23 (1.11-1.36); **1.54 (1.11-2.14)</td>
<td>In PRIME: NRI (p&lt;0.05)</td>
</tr>
<tr>
<td>Rotterdam Study (N=2,032 men aged 67,8 years on average and 3,031 women aged 69,8 years on average, Rotterdam, the Netherlands)</td>
<td>CV event in men (224), in women (196)</td>
<td>average of 4.6 years (men) and 4.9 years (women)</td>
<td>CV events male: **2.32 (1.55-2.70) female 3.08 (1.91-3.74); CHD male **2.01 (1.14-2.59) female 2.95 (1.30-4.55); stroke male: **2.06 (0.91-3.18) female 2.07 (1.00-2.97)</td>
<td>CV events male: AUC from 0.661 to 0.694 female 0.129-0.761; CHD male: AUC from 0.676 to 0.691 female from 0.726 to 0.761; stroke male: AUC from 0.699 to 0.714 female 0.721 to 0.734 p&lt;0.05 for all</td>
<td>Rutten 2010 (80)</td>
</tr>
<tr>
<td>Iwate-Kenpoku Cohort (Iwate-KENCO) (N=13,466 subjects aged &gt;40 years residents of the Ninohe, Kuji and Miyako districts, Japan)</td>
<td>Stroke (102)</td>
<td>average of 2.8 years</td>
<td>Stroke: *1.70 (1.17-2.45) in men; 1.69 (1.04-2.75) in women; **2.83 (1.29-6.20) in men; 3.61 (1.01-12.93 in women)</td>
<td>Not provided</td>
<td>Takahashi 2009 (77)</td>
</tr>
<tr>
<td>MDC (N=5,067 participants aged 58 years on average, in Malmö, Sweden)</td>
<td>CVE (418)</td>
<td>median of 12.8 years</td>
<td>CVE: *1.22 (1.10-1.36)</td>
<td>CVE: AUC from 0.758 to 0.765 n.s.</td>
<td>Melander 2009 (16)</td>
</tr>
<tr>
<td>ULSAM (N=1,135 participants with mean age, 71 years at baseline, Uppsala, Sweden)</td>
<td>CV mortality (136)</td>
<td>median of 10.0 years</td>
<td>CV mortality: *2.16 (1.55-3.00); **4.69 (2.53-8.72)</td>
<td>From 0.688 to 0.722 n.s.</td>
<td>Zethelius 2008 (9)</td>
</tr>
<tr>
<td>Sample of the Rancho Bernardo Study (N=957 people aged 60 to 97 years, US)</td>
<td>CV mortality (92)</td>
<td>median of 6.8 years</td>
<td>CV mortality: *1.85 (0.94-3.64)</td>
<td>AUC: from 0.597 to 0.725 (p &lt; 0.001)</td>
<td>Daniels 2008 (60)</td>
</tr>
<tr>
<td>Sixth examination of the Framingham Offspring Study (N=3,209 people aged on average 59±10, Framingham, US)</td>
<td>Major CVE (169)</td>
<td>median of 7.4 years</td>
<td>Major CVE: *1.25 (p&lt;0.05)</td>
<td>Reclassification of 17% of participants as high risk</td>
<td>Wang 2006 (31)</td>
</tr>
<tr>
<td>Study</td>
<td>Participant Details</td>
<td>Event</td>
<td>Median or Years</td>
<td>HR (95% CI)</td>
<td>AUC (n.s.)</td>
</tr>
<tr>
<td>-------</td>
<td>---------------------</td>
<td>-------</td>
<td>----------------</td>
<td>------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Olsen 2007 (15)</td>
<td>N=2,656 individuals aged 41, 51, 61, and 71 years old from the population near Glostrup University Hospital, Denmark</td>
<td>CEP (219)</td>
<td>9.4 years</td>
<td>CEP: *1.64 (1.42-1.90)</td>
<td>CEP: AUC from 0.82 to 0.83 n.s.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CV death (136)</td>
<td></td>
<td>CV death: *1.99 (1.65-2.40)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laukkanen 2006 (79)</td>
<td>KIHD study (N=905 men aged 46-65 years from eastern Finland)</td>
<td>CVD Death (58)</td>
<td>median of 9.8 years</td>
<td>CVD death: *1.41 (1.21-1.65);</td>
<td>Not provided</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CHD death (40)</td>
<td></td>
<td>CHD death 1.44 (1.22-1.70)</td>
<td></td>
</tr>
<tr>
<td>Kistorp 2005 (35)</td>
<td>Copenhagen Study (N=764 participants aged 50 to 89 years from the municipality of Frederiksberg, Denmark)</td>
<td>First major CVE (65)</td>
<td>median of 5.0 years</td>
<td>1st major CVE: **3.24 (1.80-5.79); *1.92 (1.42-2.56)</td>
<td>Not provided</td>
</tr>
</tbody>
</table>

N, number; HR, hazard ratio; RR, relative risk; TRF, traditional risk factors; CV, cardiovascular; CVE, cardiovascular events; CE, coronary events; MI, myocardial infarction; CEP, combined CV endpoint (CV death, stroke, or MI); TIA, transient ischemic attack; n.s. non significant; NRI, Net reclassification improvement; IDI, individual discrimination improvement; PREVEND, Prevention of Renal and Vascular End-stage Disease; KIHD, Kuopio Ischemic Heart Disease Risk Factor Study; ULSAM, Uppsala Longitudinal Study of Adult Men; PRIME, Belfast Prospective Epidemiological Study of Myocardial Infarction; MDC, Malmö Diet and Cancer.

*HR in Relation to a 1-SD Increment of plasma BNP/NT-pro-BNP (in some studies the value of BNP/NT-pro-BNP was log transformed).

** HR in the highest BNP/NT-pro-BNP category with respect to the reference (lowest) BNP/NT-pro-BNP category.
### Supplementary table 3: Intima Media Thickness (IMT) and prediction of future cardiovascular events in the community (general population).

<table>
<thead>
<tr>
<th>Population</th>
<th>Cardiovascular outcome</th>
<th>Follow-up</th>
<th>Results after adjustment for TRF</th>
<th>Discrimination and reclassification on top of TRF</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARIC (N=13,145 adults aged 45 and 64 years of age from 4 U.S. communities)</td>
<td>CHD (1812)</td>
<td>average 15.1 years</td>
<td>Not provided</td>
<td><strong>CHD: AUC form 0.742 to 0.755 p&lt;0.05</strong>; **Reclassification to high risk: 20.5%</td>
<td>Nambi 2010 (108)</td>
</tr>
<tr>
<td>ARIC (N=13,560 adults aged 45 and 64 years of age from 4 U.S. communities)</td>
<td>Stroke (703)</td>
<td>average 15.7 years</td>
<td>Hemorrhagic stroke: <strong>2.34 (0.99-5.58)</strong>; Ischemic stroke: <strong>2.42 (1.73-3.38)</strong></td>
<td>Not provided</td>
<td>Ohira 2010 (95)</td>
</tr>
<tr>
<td>CAPS (N=4,904 aged 19-90 years from 5 study sites in Western Germany,)</td>
<td>CHD (416)</td>
<td>average of 8.5 years</td>
<td>CHD: <strong>1.089 p&lt;0.05</strong></td>
<td>CHD: AUC from 0.729 to 0.732 n.s.</td>
<td>Lorenz 2010 (90)</td>
</tr>
<tr>
<td>CCCC (N=2,190 adults aged ≥35 years from the Chin-Shan township, China)</td>
<td>CHD (68) stroke (94)</td>
<td>median 10.5 years</td>
<td>CHD: <strong>1.38 (1.12-1.70)</strong>; stroke: <strong>1.47 (1.28-1.69)</strong></td>
<td>CHD: AUC from 0.787 to 0.798 n.s.</td>
<td>Chien 2008 (103)</td>
</tr>
<tr>
<td>ARIC (N=13,560 adults aged 45 and 64 years of age from 4 U.S. communities)</td>
<td>Stroke (1812)</td>
<td>average 15.1 years</td>
<td>Not provided</td>
<td><strong>CHD: AUC form 0.742 to 0.755 p&lt;0.05</strong>; **Reclassification to high risk: 20.5%</td>
<td>Nambi 2010 (108)</td>
</tr>
<tr>
<td>CHD (159)</td>
<td>Stroke (115)</td>
<td>average of 12.7 years</td>
<td>Not specified (nearly 5 (3-10))</td>
<td>Stroke: AUC from 0.864 to 0.876 n.s.</td>
<td>Prati 2008 (94)</td>
</tr>
<tr>
<td>MESA (N=6,698 adults aged 45-84 years from the populations near 6 field centers, US)</td>
<td>CHD (1812) stroke (59) CVD (222)</td>
<td>median 3.9 years</td>
<td>CVD: <strong>1.2 (1.0-1.3)</strong>; **1.7 (1.2-2.5); CHD: 1.1 (1.0-1.3); **1.7 (1.1-2.7); Stroke: **1.3 (1.1-1.7); **1.8 (0.9-3.6)</td>
<td>CVD: AUC from 0.772 to 0.782 n.s.</td>
<td>Folsom 2008 (102)</td>
</tr>
<tr>
<td>(N=1,249 aged 18 to 99 years from San Daniele Township, Italy)</td>
<td>MI (595), stroke (613), CVD related mortality (696), Composite CVD (1904)</td>
<td>till 12 years</td>
<td>MI: <strong>1.80 (1.37-2.38)</strong> stroke: <strong>1.77 (1.36-2.30)</strong> CVD related mortality: <strong>2.15 (1.65-2.80)</strong> Composite CVD: **1.84 (1.54-2.20)</td>
<td>MI: AUC from 0.680 to 0.697 n.s.</td>
<td>Cao 2007 (24)</td>
</tr>
<tr>
<td>The Tromso study (N=6,226 aged 25 to 84 years, Tromso, Norway)</td>
<td>MI (295)</td>
<td>median 5.8 years</td>
<td>MI: <strong>1.73 (0.98-3.06) in men</strong>; MI: <strong>2.86 (1.07-7.65) in women</strong></td>
<td>Stroke: from 0.686 to 0.698 n.s.</td>
<td>Not provided</td>
</tr>
<tr>
<td>CAPS (N=5,056 aged 19-90 years from 5 study sites in Western Germany,)</td>
<td>MI (228) Stroke (107)</td>
<td>average of 4.2 years</td>
<td>MI: **1.16 (1.05-1.27); **1.83 (0.97-3.45) Stroke 1.11 (0.97-1.28), **1.82 (0.64-5.16)</td>
<td>CVD mortality: from 0.742 to 0.763 n.s.</td>
<td>Not provided</td>
</tr>
<tr>
<td>MDC (N=5,163 aged 46-68 years in Malmo, Sweden)</td>
<td>Stroke (86)</td>
<td>median of 7 years</td>
<td>Stroke: **2.54 (1.20-5.40)</td>
<td>Composite CVD: from 0.684 to 0.701 n.s.</td>
<td>Rosvall 2005 (92)</td>
</tr>
<tr>
<td>MDC (N=5,163 aged 46-68 years in Malmo, Sweden)</td>
<td>CHD (113)</td>
<td>median of 7 years</td>
<td>CHD: 1.23 (1.07-1.41)</td>
<td>Not provided</td>
<td>Rosvall 2005 (93)</td>
</tr>
<tr>
<td>Rotterdam Study (N=6,389 subjects aged ≥55 years in Rotterdam, the Netherlands)</td>
<td>MI (258) Stroke (34)</td>
<td>max. of 10 years</td>
<td>MI: <strong>1.95 (1.19-3.19) in subjects with severe atherosclerosis</strong></td>
<td>Not provided</td>
<td>Van der Meer 2004 (91)</td>
</tr>
<tr>
<td>N=1,289 men aged 60 to 74 in 1 urban and 2</td>
<td>Stroke (5)</td>
<td>over 4.5-year</td>
<td>Stroke: **5.2 (1.8-14.6)</td>
<td>Not provided</td>
<td>Kitamura 2004 (98)</td>
</tr>
<tr>
<td>Study/Population</td>
<td>Event Type (N/Max Years or Avg Years)</td>
<td>Average Follow-up</td>
<td>Hazard Ratio (95% CI)</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------------------</td>
<td>-------------------</td>
<td>-----------------------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>CHS (N=5,417 participants aged 65 years or older without preexisting stroke or chronic atrial fibrillation)</td>
<td>Ischemic stroke (469) 10.2 years</td>
<td></td>
<td>Ischemic stroke: **1.07 (1.02-1.12)</td>
<td>Not provided</td>
<td></td>
</tr>
<tr>
<td>Rotterdam Study (N=5,479 subjects aged ≥55 years in Rotterdam, the Netherlands)</td>
<td>Stroke (378) average of 6.1 years</td>
<td></td>
<td>Stroke: *1.28 (1.15-1.44), **2.42 (1.51-3.89)</td>
<td>Not provided</td>
<td></td>
</tr>
<tr>
<td>Rotterdam Study (N=2,267 subjects aged ≥55 years in Rotterdam, the Netherlands)</td>
<td>MI (194) average of 4.6 years</td>
<td></td>
<td>MI: **5.95 (2.65-13.34), *1.46 (1.26-1.69)</td>
<td>Not provided</td>
<td></td>
</tr>
<tr>
<td>ARIC (N=13,145 adults aged 45 and 64 years of age from 4 U.S. communities)</td>
<td>Stroke (199) median 7.4 years</td>
<td></td>
<td>Stroke: 1.36 (1.16-1.59) in women MI: 1.21 (1.05-1.39) in men</td>
<td>Not provided</td>
<td></td>
</tr>
<tr>
<td>ARIC (N=4,476 participants aged 65 years or older without preexisting stroke or chronic atrial fibrillation)</td>
<td>Stroke+MI (496) median of 6.2 years</td>
<td></td>
<td>**3.15 (2.19-4.52) *1.36 (1.25-1.47)</td>
<td>Not provided</td>
<td></td>
</tr>
<tr>
<td>Subsample of the Rotterdam Study (N=5,130 subjects aged ≥55 years in Rotterdam, the Netherlands)</td>
<td>N=1,567 Stroke (95) max of 4 years</td>
<td></td>
<td>Stroke: *1.34 (1.08-1.67), **2.81 (1.20-6.56)</td>
<td>Not provided</td>
<td></td>
</tr>
<tr>
<td>ARIC (N=7,289 women and 5,552 men aged 45 and 64 years of age from 4 U.S. communities)</td>
<td>CHD (290) range of 4-7 years</td>
<td></td>
<td>CHD: *1.42 (1.24-1.64) **3.76 (1.68-8.43) in women CHD: **1.18 (1.06-1.32), **2.02 (1.32-3.09) in men</td>
<td>Not provided</td>
<td></td>
</tr>
</tbody>
</table>

N, number; HR, hazard ratio; RR, relative risk; TRF, traditional risk factors; CV, cardiovascular; CVE, cardiovascular events; CE, coronary events; MI, myocardial infarction; CEP, combined CV endpoint (CV death, stroke, or MI); TIA, transient ischemic attack; n.s. non significant; NRI, Net reclassification improvement; IDI, individual discrimination improvement; ARIC, Atherosclerosis Risk in Communities MESA, the Multi-Ethnic Study of Atherosclerosis; CCCC, Chin-Shan Community Cardiovascular Cohort Study, CAPS, Carotid Atherosclerosis Progression Study; CHS, Cardiovascular Health Study; MDC, Malmö Diet and Cancer.

* HR for an Incident CVD, CHD, or Stroke Event in Relation to a 1-SD Increment of Maximal Carotid IMT.

**HR in the highest IMT category with respect to the reference (lowest) IMT category.

N.B. the site where IMT was evaluated is different for different studies (where available the average value of different sites or common carotid IMT was taken).
## Supplementary table 4: Coronary Artery Calcium and prediction of future cardiovascular events in the community (general population).

<table>
<thead>
<tr>
<th>Population</th>
<th>Cardiovascular outcome (n.)</th>
<th>Follow-up</th>
<th>Results after adjustment for TRF</th>
<th>Discrimination and reclassification</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>HNR study (N=4,129 subjects aged 45 to 75 years, in the metropolitan Ruhr area, Germany)</td>
<td>MI+CHD death (93)</td>
<td>median of 5 years</td>
<td>MI+CHD death: **6.40 (3.12-13.12), *1.27 (1.18-1.37)</td>
<td>MI+CHD death: *AUC from 0.681 to 0.749 p&lt;0.01</td>
<td>Erbel 2010 (117)</td>
</tr>
<tr>
<td>MESA (N=5,878 adults aged 62.2 years on average, from the populations near 6 field centers, US)</td>
<td>CHD (209)</td>
<td>median of 5.8 years</td>
<td>CHD: *1.41 (1.31-1.51)</td>
<td>CHD: *IDI 0.026 (p&lt;0.001), NRI 0.25 p&lt;0.001</td>
<td>Polonsky 2010 (116)</td>
</tr>
<tr>
<td>Sample of the Rotterdam Study (N=2,028 asymptomatic participants, aged 69.6±6.2 years)</td>
<td>Hard CE (135)</td>
<td>median of 9.2 years</td>
<td>Hard CE: *1.33 (1.21-1.4)</td>
<td>AUC from 0.72 to 0.76 p&lt;0.05; Model fit Likelihood χ²=120.32, p&lt;0.001</td>
<td>Elias-Smale 2010 (118)</td>
</tr>
<tr>
<td>MESA (N=6,722 adults aged 62.2 years on average, from the populations near 6 field centers, US)</td>
<td>Total CE (162)</td>
<td>median of 3.8 years</td>
<td>Major CE : **6.84 (2.93-15.99); total CE 9.67 (5.20-17.98); Major CE: *1.20 (1.12-1.29); total 1.26 (1.19-1.33)</td>
<td>Total CE: AUC from 0.77 to 0.82; p&lt;0.05 major CE: AUC from 0.79 to 0.83; p&lt;0.05</td>
<td>Detrano 2008 (119)</td>
</tr>
<tr>
<td>MESA (N=6,698 adults aged 45-84 years from the populations near 6 field centers in US)</td>
<td>CHD (159)</td>
<td>median of 3.9 years</td>
<td>CVD: *1.9 (1.6-2.2), **4.4 (2.8-6.8); Stroke: *2.5 (1.9-2.8), **8.2 (4.5-15.1); Stroke: *1.1 (0.8-2.4), **1.0 (0.5-2.1)</td>
<td>CVD: AUC from 0.772 to 0.808 n.s. CHD: AUC from 0.772 to 0.823 n.s.</td>
<td>Folsom 2008 (102)</td>
</tr>
<tr>
<td>St. Francis Heart Study (N=4,903 subjects aged 50 to 70 years)</td>
<td>ASCVD (119)</td>
<td>average of 4.3 years</td>
<td>ASCVD: calcium score predicted CAD events independently of standard risk factors</td>
<td>ASCVD: AUC from 0.68 (TRF only) to 0.79 (CAC only) p&lt;0.05; enhanced reclassification (p&lt;0.0001)</td>
<td>Arad 2005 (120)</td>
</tr>
<tr>
<td>Sample of the Rotterdam Study (N=1,795 asymptomatic participants aged 62- 85 years, in Rotterdam, the Netherlands)</td>
<td>Hard CHD (190)</td>
<td>median of 3.3 years</td>
<td>CVD: **3.9 (2.1-7.3); CHD: **8.3 (3.3-21.1) hard CHD: **8.1 (2.9-22.3)</td>
<td>CHD: AUC from 0.749 to 0.774; hard CHD to 0.762; CVD to 0.752; p&lt;0.05 for all</td>
<td>Vliegenthart 2005 (113)</td>
</tr>
<tr>
<td>Preventive medical examination at the Cooper Clinic (N=6,835 men and 3911 women aged 22-96 years, in Dallas, US)</td>
<td>Hard CE (81)</td>
<td>average of 3.5 years</td>
<td>Hard CE: **Men 17.7 (5.1-61.8); women 7.2 (0.8-12.5)</td>
<td>Not provided</td>
<td>LaMonte 2005 (115)</td>
</tr>
<tr>
<td>South Bay Heart Watch (N=1,029 aged &gt;45 years)</td>
<td>MI+CHD death (84)</td>
<td>median of 7.0 years</td>
<td>MI+CHD death: *1.4 (1.2-1.5)</td>
<td>MI+CHD death: AUC from 0.63 to 0.68; p&lt;0.01</td>
<td>Greenland 2004 (116)</td>
</tr>
<tr>
<td>Rotterdam Study (N=5,631 subjects aged ≥55years in Rotterdam, the Netherlands)</td>
<td>Stroke (378)</td>
<td>average of 6.1 years</td>
<td>Stroke: *1.21 (1.10-1.33), **1.63 (1.06-2.52)</td>
<td>Not provided</td>
<td>Hollander 2003 (101)</td>
</tr>
</tbody>
</table>
N, number; HR, hazard ratio; RR, relative risk; TRF, traditional risk factors; CV, cardiovascular; CVE, cardiovascular events; CE, coronary events; MI, myocardial infarction; CEP, combined CV endpoint (CV death, stroke, or MI); TIA, transient ischemic attack; n.s. non significant; NRI, Net reclassification improvement; IDI, individual discrimination improvement; HNR, Heinz Nixdorf Recall study; MESA, the Multi-Ethnic Study of Atherosclerosis.

*Hazard Ratios (HRs) in Relation to a 1-SD Increment of CAC Score (in some studies the CAC was log transformed).

**HR in the highest CAC Score category with respect to the reference (lowest) CAC Score category.